drugset
Drugs / Bystander-Based Autologous Tumor Cell Vaccine
last change Mar 2010 re-read 3 minutes ago

Bystander-Based Autologous Tumor Cell Vaccine

Vaccine

Developed for
cutaneous melanoma
Investigated by
American Society of Clinical Oncology · H. Lee Moffitt Cancer Center and Research Institute · National Cancer Institute (NCI) · Society of Surgical Oncology (SSO)

Trials 1

today NCT00101166 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00101166 Oct 2004 → Mar 2010 cutaneous melanoma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bystander-Based Autologous Tumor Cell Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101166 ↗
Modality Vaccine “new cancer vaccine” NCT00101166 ↗